Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Fig. 7

Validation analysis using the TCGA 677 CRC tumor dataset. (a) Scatter plots of the 18-gene MEK activation vs. the 13-gene MEKi bypass (BP) and the 13-gene MEKi BP vs. SRC activation signature scores in TCGA 677 CRCs. Higher (> 0 median) vs lower (< 0, median) scores are indicated by red vs blue colors. (b) Spearman correlation heatmap of the signature scores and CMS1*, CMS2*, CMS3* and CMS4* scores (measuring a propensity of a tumor to fall into CMS1, CMS2, CMS2 and CMS4 classes, respectively) in TCGA 677 CRC tumors. (c) Comparison of the signature scores among the CMS1-4 subtypes (n = 611). Bars represent Mean with standard errors (SEM). P values are for two-tailed Mann Whitney test. (d) Scatter plots of Hu-Lgr5-ISC, Hu-EphB2-ISC, Hu-Late TA, and Hu-Proliferation vs EMT signature scores. The CMS1-4 subtypes are indicated by red (CMS4) vs orange (CMS3) vs green (CMS2) vs blue (CMS1) colors

Back to article page